CRISPR Cas12a2 Kills Cells When RNA Detected
The simplest story about CRISPR is that it edits genes. That story is not wrong, but it is incomplete. The well-known CRISPR-Cas9 system finds a specific stretch of DNA, guided by its built-in RNA, and cuts it. That cut can delete a gene or insert a new one. For years, this has been the dominant narrative: CRISPR equals DNA surgery. Then in early May 2025, a team of researchers published a paper in Nature that upends that straightforward version. They describe a molecular machine that does something entirely different—and far more dangerous to a target cell.
The machine is called CRISPR-Cas12a2. Unlike Cas9, which searches for matching DNA, Cas12a2 searches for matching RNA. When it finds that RNA inside a living cell, it does not stop at a targeted cut. Instead, it activates a brutal, indiscriminate response: it shreds every piece of double-stranded DNA it can reach within that cell. The damage is widespread. The cell cannot repair it. It enters cell-cycle arrest and then, primarily, undergoes programmed cell death—apoptosis. This is not a gene edit. It is a cell execution triggered by a single RNA signal.
The discovery was made by an international team of scientists. The lead authors include Paul Scholz, Jared Thompson, and Kadin T. Crosby, alongside colleagues from the University of Utah, Utah State University, Akribion Therapeutics, the Helmholtz Institute for RNA-based Infection Research, and the University of Wuerzburg. Ryan Jackson, a biochemist at Utah State University, called the result “a holy grail of medicine and other sciences.” The work was supported by the National Institutes of Health and the R. Gaurth Hansen Family. What they built is a programmable kill switch that only flips when a specific RNA molecule is present.
Akribion and the First Targets
The technology has already been tested against real human threats. The team that will first apply this finding includes Akribion Therapeutics, which co-led the study In the laboratory, they programmed Cas12a2 to recognize several biologically important RNA sequences. They then observed whether the system could eliminate cells that contained those sequences. It worked in every case they tested.
First, they targeted human cells infected with high-risk human papillomavirus, known as HPV. The cells carrying the viral RNA were destroyed. Second, they targeted cells that had failed a previous attempt at CRISPR gene editing—cells that contained an unwanted editing outcome. Cas12a2 eliminated those failed cells. Third, they targeted cells carrying a common cancer-causing mutation in the KRAS gene. That mutation is a frequent driver in many cancers, and Cas12a2 killed only the cells that expressed the mutated RNA. [3] In all these tests, the researchers found no off-target activation. Cells that lacked the target RNA were completely spared. The system distinguished diseased from healthy with nothing more than a single RNA difference.
The actor behind this translation is Akribion Therapeutics, a biotechnology company that participated directly in the research. Their scientists worked alongside the academic groups to validate the tool in human cell lines and yeast. Ryan Jackson and Kadin T. Crosby, both at Utah State University, represent the academic side. The combination of a commercial partner and university labs suggests a clear path forward: the method can be refined, scaled, and eventually delivered to patients. The paper describes the work as “programmable and sequence-specific cell elimination.” It is a precise biological scalpel.
What Becomes Possible and What Remains Locked
To understand what this finding changes, compare it to the existing options for eliminating unwanted cells with CRISPR. The first option, Cas9, can be used to kill cells, but it has important limitations. Cas9 must target highly repetitive DNA regions, and it cannot directly respond to a cell’s current gene expression. A cell can be dead without ever making the problematic protein. The second option, Cas13, targets RNA, but its effectiveness often drops when the activity of the targeted RNA is low.
Cas12a2 solves both problems. The paper states it can enact potent cell killing only in the presence of a recognized transcript. [2] That means the cell must be actively expressing the target RNA—it is alive and making the thing that gets it killed. It can also achieve single-nucleotide resolution specificity. [2] A single letter difference in the RNA sequence can be enough to spare a healthy cell. And it can be triggered by poorly expressed transcripts—even a tiny number of RNA molecules can set off the destruction. For cancer, viruses, and autoimmune diseases, this combination is exactly what has been missing.
But the finding leaves many questions open. The researchers emphasize that Cas12a2 is still an experimental technology. All the work was performed in yeast and cultured human cell lines, not in patients. No clinical applications exist yet. Future studies will focus on improving delivery methods—how to get Cas12a2 into the right cells in the body. They will also work on increasing targeting flexibility, reducing any potential off-target activation, and understanding how different cell types respond to the DNA damage. Another critical question is how the immune system reacts when targeted cells are destroyed. That reaction could either help or hinder future cancer immunotherapies. As the authors conclude, Cas12a2 is poised to expand the CRISPR toolbox to incorporate programmable cell elimination. The tool is ready. The applications are not.